Drugs / TBI-1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02096614 | Apr 2014 → Mar 2021 | cancer | Mie University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02096614 ↗ |
| Modality | Cell therapy | “MAGE-A4-specific TCR gene transduced T lymphocytes are transferred to the patients with MAGE-A4-expressing solid tumors.” NCT02096614 ↗ |
| Target | MAGEA4 | “MAGE-A4-specific TCR gene transduced T lymphocytes are transferred to the patients with MAGE-A4-expressing solid tumors.” NCT02096614 ↗ |